For research use only. Not for therapeutic Use.
CXL146 is a selective inhibitor of HL60/MX2 cell proliferation by targeting GRP78 overexpression. CXL146 treatment activated the unfolded protein response (UPR). CXL146-induced UPR activation led to a series of downstream events, including extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase activation, which contributed to CXL146-induced apoptosis.
KEYWORDS: CXL146 | supplier | GRP78 inhibitor | CXL 146 | CXL-146 | CAS [2244586-41-0] | Unfolded Protein Response (Non Selective) | Hsp70 | Inhibitor | Enzymes | GRP78 | Multidrug resistance | HSPA5 | Binding immunoglobulin protein | BiP | ER stress
| Catalog Number | I047657 |
| CAS Number | 2244586-41-0 |
| Molecular Formula | C24H20N2O5 |
| Purity | ≥95% |
| IUPAC Name | prop-2-ynyl 2-amino-6-(2-methylpyridin-4-yl)-4-(2-oxo-2-prop-2-ynoxyethyl)-4H-chromene-3-carboxylate |
| InChI | InChI=1S/C24H20N2O5/c1-4-10-29-21(27)14-19-18-13-16(17-8-9-26-15(3)12-17)6-7-20(18)31-23(25)22(19)24(28)30-11-5-2/h1-2,6-9,12-13,19H,10-11,14,25H2,3H3 |
| SMILES | CC1=NC=CC(=C1)C2=CC3=C(C=C2)OC(=C(C3CC(=O)OCC#C)C(=O)OCC#C)N |
| Reference | T Bian et al. Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells. J Med Chem. 2018 Aug 9;61(15):6892-6903. T Bian at al. CXL146, a Novel 4 H-Chromene Derivative, Targets GRP78 to Selectively Eliminate Multidrug-Resistant Cancer Cells. Mol Pharmacol. 2020 Jun;97(6):402-408. |
